Top Markets
Coin of the day
Actuate Therapeutics Inc Actuate Therapeutics Inc

Actuate Therapeutics Inc

ACTU
Rank in Stocks #28698
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the... Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Share Price
$1.05
Market Cap
$25.12M
Change (1 day)
0.00%
Change (1 year)
-86.83%
Country
US
Trade Actuate Therapeutics Inc (ACTU)

Category

Earnings for Actuate Therapeutics Inc (ACTU)
Earnings in 2026 TTM: 0
According to Actuate Therapeutics Inc latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Actuate Therapeutics Inc from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$-3.09B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH